|16. Switch to a TNFi monoclonal antibody biologic over an IL-17i biologic (PICO 59)|Moderate (50)|
|Strong recommendation supported by moderate-quality evidence showing monoclonal antibody TNFi biologics are effective for IBD while an IL-17i biologic is not effective for IBD.|Strong recommendation supported by moderate-quality evidence showing monoclonal antibody TNFi biologics are effective for IBD while an IL-17i biologic is not effective for IBD.|
|17. Switch to a TNFi biologic monoclonal antibody biologic over an IL-12/23i biologic (PICO 61)|Very low|